ArticleIntensive care medicine experimental2020
In vitro characterization of PrismaLung+: a novel ECCO
Article in Intensive care medicine experimental, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- A prospective clinical evaluation of new ECCO2R technology in mild to moderate ARDS patients: assessing ultra-lung-protective ventilation with PRISMALUNG.Critical care (London, England) · 2026Article
- Additional Carbon Dioxide Removal by Oxygenated Dialysis Fluid: Insights for the Development of a Novel Lung and Kidney Assist Device.ASAIO journal (American Society for Artificial Internal Organs : 1992) · 2026Article
- Questioning the classification of "high blood flow" versus "low blood flow" ECCO₂R in ultra-low tidal volume ventilation studies: a call for functional classification.Critical care (London, England) · 2025Article
- Recent Advances and Future Directions in Extracorporeal Carbon Dioxide Removal.Journal of clinical medicine · 2024Review
- Is there still a place for ECCOMedizinische Klinik, Intensivmedizin und Notfallmedizin · 2024Review
- Evaluation of the safety and efficacy of extracorporeal carbon dioxide removal in the critically ill using the PrismaLung+ device.European journal of medical research · 2023Article
- Safety and Effectiveness of Carbon Dioxide Removal CO2RESET Device in Critically Ill Patients.Membranes · 2023Article
- Ultraprotective Ventilation via ECCO2R in Three Patients Presenting an Air Leak: Is ECCO2R Effective?Journal of personalized medicine · 2023Article
- Alkaline Liquid Ventilation of the Membrane Lung for Extracorporeal Carbon Dioxide Removal (ECCOMembranes · 2021Article
- Comparison of Circular and Parallel-Plated Membrane Lungs for Extracorporeal Carbon Dioxide Elimination.Membranes · 2021Article
- Evaluation of a New Extracorporeal COMembranes · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 4 countries.
Funding
Abstract
backgroundInvasive mechanical ventilation is lifesaving in the setting of severe acute respiratory failure but can cause ventilation-induced lung injury. Advances in extracorporeal CO
methodsThe in vitro CO
resultsThe PrismaLung+ device performed similarly to the A.L.ONE device, with both devices demonstrating CO
conclusionsThe newly developed PrismaLung+ performed more effectively than PrismaLung, with performance of CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.